NCT05872867 - Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

February 22, 2026

Study Completion Date

February 22, 2026

Conditions

Advanced Solid TumorMetastatic Solid TumorLung CancerColorectal CancerPancreatic CancerCholangiocarcinomaHead and Neck CancerNon Small Cell Lung Cancer

Interventions

BIOLOGICAL

WM-A1-3389

Anti-IGSF1 (Immunoglobulin superfamily member 1)

BIOLOGICAL

Pembrolizumab

Anti-PD-1(Programmed cell death protein 1)

Trial Locations (2)

21999

RECRUITING

Incheon St. Mary's Hospital, Incheon

06591

RECRUITING

Seoul St. Mary's Hospital, Seoul